Ardelyx shares dropped nearly 8% pre-market after missing fourth-quarter earnings expectations. Despite this, HC Wainwright raised its price target by 80% to $18, citing a new patent for Ibsrela and Xpozah that expires in 2042. The firm maintained a Buy rating, encouraged by the strengthened intellectual property protection for its key commercial products.